KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Q3 2025 value amounting to $129000.0.

  • Supernus Pharmaceuticals' Capital Expenditures fell 3550.0% to $129000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 13613.45%. This contributed to the annual value of $725000.0 for FY2024, which is 3157.89% up from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Capital Expenditures stood at $129000.0, which was down 3550.0% from $455000.0 recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Capital Expenditures peaked at $851000.0 during Q1 2022, and registered a low of -$271000.0 during Q2 2022.
  • Moreover, its 4-year median value for Capital Expenditures was $179500.0 (2023), whereas its average is $185642.9.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Capital Expenditures plummeted by 6733.25% in 2023 and then soared by 69166.67% in 2024.
  • Over the past 4 years, Supernus Pharmaceuticals' Capital Expenditures (Quarter) stood at -$168000.0 in 2022, then surged by 78.57% to -$36000.0 in 2023, then skyrocketed by 691.67% to $213000.0 in 2024, then plummeted by 39.44% to $129000.0 in 2025.
  • Its last three reported values are $129000.0 in Q3 2025, $455000.0 for Q2 2025, and $327000.0 during Q1 2025.